Dexcom stock rises 4.14 percent to EUR 77.90, 35.05 percent below average volume

Published on 10/15/2026 at 21:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mizuho set a USD 100.00 target on October 13, 2026. Dexcom stock costs EUR 77.90 on October 15, 2026, up 4.14 percent versus the Xetra close.

Price action and analyst view

Dexcom stock traded 4.14 percent higher at Lang & Schwarz on October 15, 2026.
Mizuho raised its Dexcom target to USD 100.00 from USD 95.00 on October 13, 2026.
Dexcom stock costs EUR 77.90 at 9:43 p.m. CEST at Lang & Schwarz on October 15, 2026, 4.14 percent above the Xetra close of October 14, 2026.
Dexcom is scheduled to report third-quarter 2026 earnings after the market closes on October 29, 2026.

NASDAQ-Tradingfloor dramatisch beleuchtet, Händler, Bildschirme mit Gesundheitscharts — Dexcom Inc. Börsen-Editorial zeigt dynamischen NASDAQ-Tradingfloor mit Gesundheitssektor-Charts für Aktionäre ISIN US2521311074, Illustration mit AI erstellt.

Dexcom Inc. (US2521311074) stock rose 4.14 percent versus the Xetra close of October 14, 2026. On October 13, 2026, Mizuho analyst Anthony Petrone raised the price target to USD 100.00 from USD 95.00 and kept an Outperform rating, as Markets Insider reported. Dexcom stock was trading at EUR 77.90 at Lang & Schwarz on October 15, 2026 at 9:43 p.m. CEST.

Target reaches USD 100.00

Mizuho's move gives investors a fresh valuation marker ahead of Dexcom's third-quarter report. The USD 5.00 increase represents a 5.26 percent rise from the former USD 95.00 target. The firm cited procedure-volume headwinds linked to the Affordable Care Act and Medicaid contraction in its earnings preview, according to Markets Insider.

Price position stays measurable

The primary Nasdaq quote stood at USD 87.42 at 3:49 p.m. ET on October 15, 2026. Dexcom's 52-week range was USD 54.11 to USD 92.59 at that time, putting the primary quote 5.58 percent below the high. Trading volume reached 2,859,452 shares against an average of 4,402,375, or 35.05 percent below the average.

Valuation and October date

Dexcom carried a market capitalization of USD 33.0 billion and a P/E ratio of 34.55 on October 15, 2026. The next scheduled catalyst is the third-quarter 2026 earnings release after the market closes on October 29, 2026, with diluted earnings per share expected at USD 0.66 versus USD 0.61 in the year-ago quarter, according to Yahoo Finance.

Comparison with peers

Dexcom Inc. (Nasdaq, USD): plus 4.14 percent, P/E 34.55, market capitalization USD 33.0 billion
Abbott Laboratories (NYSE, USD): plus 2.25 percent, P/E 33.65, market capitalization USD 181.1 billion
Insulet (Nasdaq, USD): plus 3.23 percent, P/E 25.86, market capitalization USD 9.6 billion

Stock snapshot after hours

The euro quotation places Dexcom above its Xetra close while the primary Nasdaq quote remains below its 52-week high. The next dated test is the October 29, 2026 earnings release, where the USD 0.66 diluted earnings-per-share estimate sets the near-term comparison.

Dexcom stock was trading at EUR 77.90 at Lang & Schwarz on October 15, 2026 at 9:43 p.m. CEST, plus 4.14 percent versus the Xetra close of October 14, 2026 at EUR 74.80. The further course of trading is shown by the continuously updated real-time quote of Dexcom stock.